Skip to content
  • Menu
  • About

    About HRI

    HRI is a leading non-governmental organisation working to reduce the negative health, social and human rights impacts of drug use and drug policy by promoting evidence-based public health policies and practices, and human rights based approaches to drugs. Read more about HRI’s history.

    Vision and Mission

    Our vision is a world in which individuals and communities benefit from drug laws, policies and practices that promote health, dignity and human rights.

    Staff

    Meet our staff at HRI

    Governance

    HRI is governed by a nine person Board of Directors, elected for three-year terms of office by our membership at our Annual General Meetings. Read more about HRI governance.

    What is harm reduction?

    Harm reduction refers to policies, programmes and practices that aim to reduce the harms associated with the use of psychoactive drugs in people unable or unwilling to stop. The defining features are the focus on the prevention of harm, rather than on the prevention of drug use itself, and the focus on people who continue to use drugs.

    Harm reduction definition and principles in 11 languages

    Contact Us

    Please feel free to contact us if you have any questions or queries about our website, our work, membership or the international harm reduction conference.

    Donors

    HRI benefits from the generous support of the Open Society Foundations, the European Commission, the Elton John AIDS Foundation, the MAC AIDS Fund, UNAIDS, the World Health Organization, the UN Office on Drugs and Crime, the World Bank, The Robert Carr Networks Fund and the Swiss Government.

    Harm Reduction International Awards

    HRI presents a number of awards at outr international conference to acknowledge the contributions of outstanding groups or individuals in the field.

  • Our Work

    Evidence for advocacy

    HRI produces groundbreaking research and policy analysis informing advocacy across our sector.

    Spending where it matters

    Funding for harm reduction services is dangerously short while billions are wasted on drug enforcement. HRI works to assess resourcing needs and advocates for a reinvestment in health.

    Human rights-based policy

    Human rights abuses and drug enforcement go hand in hand. HRI challenges laws, policies and practices that generate harm.

    Sector strengthening

    HRI builds advocacy coalitions and supports emerging harm reduction networks to strengthen the international harm reduction sector.

    International conference

    Harm reduction is a global movement. Our biennial gathering is the International Harm Reduction Conference, convened by HRI.

  • Global State of Harm Reduction

    Global State of Harm Reduction

    Our flagship publication is the biennial Global State of Harm Reduction report. First published in 2008, it involves a coordinated effort across practitioners, academics, advocates and activists to map global data and responses to HIV and hepatitis C epidemics related to unsafe injecting and non-injecting drug use. It is the only report to provide an independent analysis of the state of harm reduction in the world. The information collated within the report is stored and regularly updated on an interactive e-tool for researchers and advocates.

    The Global State of Harm Reduction report is supplemented by regular thematic reports and advisories on key issues and emerging challenges. Please search our Resource Library for more information or join our e-list for regular updates.

    Interactive e-tool

    Global State of Harm Reduction’ e-tool is an interactive resource containing up-to-date information on harm reduction policy and programming around the world. Users can select countries or regions and create tables for an at-a-glance guide to the current state of harm reduction worldwide.

  • International Conferences

    International Conferences

    The 24th International Harm Reduction Conference 2015 will take place in Kuala Lumpur, Malaysia, 18–21 October, 201

    Sign up for e-updates or visit the website regularly for more information.

    You can still access the 2013 conference site for an idea of what to expect.

    Conference Archive

    Explore past international harm reduction conferences dating back to 2000.

  • Resource Library

    Resource Library

    Use our extensive resource library to search for HRI, NGO and academic reports, articles and presentations, including materials from past international conferences.

    Harm Reduction Journal

    Harm Reduction Journal, www.harmreductionjournal.com, is an open access, peer-reviewed, online journal whose focus is on the prevalent patterns of psychoactive drug use, the public policies meant to control them, and the search for effective methods of reducing the adverse medical, public health, and social consequences associated with both drugs and drug policies.

  • Support Us

    Membership & Donations

    HRI is a membership based organisation with over 8,000 members worldwide. Read more about individual and organisational membership here.

    We rely on trusts, grants, membership fees and donations to continue our work. To make a donation or pay membership fees, please use our secure payment page.

    Or why not fundraise for us with ‘Discover Adventure’?

    Contact Us

    Harm Reduction International
    Unit 2C09 Southbank Technopark
    90 London Road
    London
    SE1 6LN  

    Tel: +44(0) 207 717 1592
    Fax: +44 (0) 207 922 8822
    Email: info@ihra.net
    Join us on facebook at: Harm Reduction International
    Or join us on Twitter at: HRInews

    E-Updates

    Sign up to receive email updates, report launches, harm reduction advisories and information about the forthcoming international harm reduction conference

Risk of HIV outbreaks among drug injectors in the EU

Date: 19 November 2011

  • Print
  • Bookmark and Share

Source = EMCDDA

Over the last decade, gains have been made within the EU in addressing HIV infection among injecting drug users — these include a greater availability of prevention, treatment and harm-reduction measures. Other factors, such as the decline in injecting drug use in several countries, are also likely to have played a role in the decrease in the number of new HIV infections.

The latest data show that the average rate of newly reported HIV cases continues to fall in Europe, reaching a low of 2.85 new cases per million population in 2009 (in total, about 1 300 cases). Here, the overall EU situation compares positively, both in a global and a wider European context (1,2).

Nevertheless, this year’s EMCDDA Annual report notes some worrying developments in respect of HIV among injecting drug users.

In July 2011, Greece — historically a low HIV-prevalence country — reported an outbreak of new HIV infections among drug injectors (170 cases at the time of writing) (3,4,5,6,7,8). Recent increases in new infections have also been reported by Bulgaria, Estonia and Lithuania, indicating a continued potential for HIV outbreaks among injecting drug users in some countries (see Figure INF-2 in the 2011 Statistical bulletin). At a recent EMCDDA meeting (October 2011), national experts noted further HIV increases among drug users in Romania and potentially worrying changes in risk factors reported in Hungary.

Despite the declines in HIV infections among drug injectors in the European Union over the last decade, complacency must be avoided. HIV infection can spread rapidly in vulnerable populations of injectors especially if service provision is low. Interventions (especially needle and syringe programmes, opioid substitution treatment, diagnosis and anti-retroviral treatment) can be effective in reducing the spread of the virus among drug injectors. Joint European guidelines on the prevention of HIV and other infections among drug injectors were launched in October 2011 by the European Centre for Disease Control and the EMCDDA.

HIV epidemics among drug injectors also continue to pose a major public health problem for many countries bordering the EU (see Annual report, Chapter 7, Figure 15) (2). Within the EU, the current financial situation means that budgets for drug services are likely to come under increased scrutiny. It is therefore important that the social and financial costs of potential new HIV outbreaks, as well as the guidance on what kinds of interventions are likely to prove most effective in this area, are borne in mind when making decisions on the provision of services.

Apart from the direction of trends over time, the actual rate of reported new HIV diagnoses (per million population) in 2009 related to injecting drug use remained relatively high in Estonia (63.4), Lithuania (34.9), Latvia (32.7), Portugal (13.4) and Bulgaria (9.7), suggesting ongoing transmission. Injecting drug use accounts for over 2 000 AIDS-related deaths a year in the EU.

Greek report on the HIV outbreak in drug injectors

Following the first warning of the outbreak in Greece (3), the EMCDDA commissioned a rapid analysis of the situation (Word document) with regard to the latest epidemiological data and prevention measures being taken. The report notes that:

  • During 2011, the number of newly reported cases of HIV infection among injecting drug users in Greece has sharply increased. By the end of July, 113 cases had been reported in the Hellenic Centre for Disease Control and Prevention’s surveillance system while, from 2001 to 2010, the number of reported cases ranged from 3 to 19 a year. There were no changes reported in testing policy that could explain this increase. The overwhelming majority of new cases have been detected in Athens.
  • Preliminary data suggest that 62% of the reported injecting drug users were of Greek origin, 15% were immigrants and 23% were of unknown ethnicity.
  • Prevalence of antibodies to HIV among injecting drug users ranged from 0.3–0.8% during the years 2002–2010. In the first seven months of 2011, a sharp increase was observed in all data sources.
  • In 2011, molecular analysis revealed that 22 out of 23 positive samples (96%) were found to belong to injecting drug user networks. Analysis suggested that the origin of the virus was from Asia (12 cases), Greece (7 cases) and from South-western Europe (Portugal and Spain) (3 cases).
  • A number of hypotheses exist in regard to the possible contributory factors for the increased number of new HIV cases: they include increased levels of sexual and drug-related risk behaviour, and the absence of comprehensive HIV-prevention programmes. It has also been suggested that other factors, including targeting of drug injectors by the police may have inhibited service uptake or encouraged more risky forms of use.
  • Considering the estimated number of problem drug users, Greece has relatively few low-threshold programmes for drug injectors. The opioid substitution programme — a measure with high efficacy in preventing HIV transmission among injecting drug users — has a waiting list of five to seven years. At the end of June 2011, 5 573 drug users were reported to be actively enrolled in opioid substitution programmes in Greece. However, it was also reported that 7 428 (3 500 in Athens) additional applications for treatment were pending, resulting in relatively low coverage of opioid substitution treatment (see Figure HSR-1 in the 2011 Statistical bulletin). All HIV-positive injecting drug users, including illegal immigrants, are offered priority access to opioid substitution treatment and anti-retroviral therapy.
  • Anonymous HIV/AIDS screening and counselling, as well as anti-retroviral therapy for HIV-positive people and their sexual partners, are provided for by law and are widely available.
  • Syringe and injecting equipment exchange or distribution programmes are available, but their coverage is very limited (see Figure HSR-3 in the 2011 Statistical bulletin).
  • A number of steps are being taken to address the HIV outbreak, with a focus on improving the availability of prevention and health interventions for drug injectors. These include:
  • Intensification of programmes providing needles, syringes and condoms in downtown Athens (January 2011);
  • A switch in the kind of syringes being offered (from high to low dead space syringes) is under way (September 2011);
  • Systematic HIV screening of injecting drug users in treatment programmes has been initiated (September 2011);
  • An awareness campaign directed at injecting drug users was implemented in the centre of Athens (March 2011);
  • A molecular epidemiology surveillance programme was initiated to describe the transmission networks, determine the origin of HIV strains and to identify index cases (May 2011);
  • A major restructuring of opioid substitution programmes is also underway, and is expected to eliminate the waiting list by the end of 2011.

 

References

(1) Wiessing, L., Likatavičius, G., Klempová, D., Hedrich, D., Nardone, A., Griffiths, P. (2009), ‘Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users’, American Journal of Public Health 99 (6), pp. 1049–52.

(2) Wiessing, L., van de Laar, M.J., Donoghoe, M.C., Guarita, B., Klempová, D., Griffiths, P. (2008), ‘HIV among injecting drug users in Europe: increasing trends in the East’, Eurosurveillance 13(50): pii=19067.

(3) Malliori, M. (2011), Early-warning message to EMCDDA, EMCDDA early-warning system report, July 2011.

(4) Paraskevis, D., Hatzakis, A. (2011), ‘An ongoing HIV outbreak among intravenous drug users in Greece: preliminary summary of surveillance and molecular epidemiology data’, EMCDDA early-warning system report, July 2011.

(5) Paraskevis, D., Nikolopoulos, G., Tsiara, C., et al. (2011), ‘HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report’, Eurosurveillance 16: 19962.

(6) EKTEPN (2010), ‘Annual report on the state of the drugs and alcohol problem’, Greek Documentation and Monitoring Centre for Drugs, Athens.

(7) EKTEPN (2011) ‘Report of the ad hoc expert group of the Greek focal point on the outbreak of HIV/AIDS in 2011’, Greek Documentation and Monitoring Centre for Drugs, Athens, EMCDDA early-warning system report, July 2011.

(8) Kentikelenis, A., Karanikolos, M., Papanicolas, I., Basu, S., McKee, M., Stuckler, D. (2011), ‘Health effects of financial crisis: omens of a Greek tragedy’, Lancet published online, October 10, 2011, DOI:10.1016/S0140-6736(11)61556-0.

blog comments powered by Disqus